News | July 28, 2008

Gold Nanoshells Help Visibly Heat and Destroy Cancer

July 29, 2008 - Most cancer tumors that have clear borders and are well defined have traditionally been treated successfully by surgical removal.

But not all cancers respond to conventional surgery. More importantly, conventional surgery brings risks of complications and long recovery periods that can negatively impact a person's quality of life.

To overcome these treatment limits, a group of researchers based at the University of Texas' M.D. Anderson Cancer Center, turned to lasers and nanotechnology. They explored an emerging minimally-invasive approach to treating tumors that delivers a lethal dose of laser-generated heat to tumors, known as thermal ablation. To improve thermal ablation,they added a nano-twist that precisely guides and concentrates heat in targeted tumors.

Working with Nanospectra Biosciences, Inc., researchers injected nanoshells made of gold silica into canine models of brain cancer. The nanoshells homed to the target tumors, where they were taken in by the tumor cells. Next, researchers irradiated the nanoparticle-filled tumor

with low-power laser light to selectively heat the tumor-but not the surrounding, healthy tissue. M.D. Anderson researchers added iron-oxide cores to the nanoshells to make them visible by magnetic resonance imaging so researchers could observe the process.

Results from these experiments were supported by numerical modeling studies, and by scanning electron microscope data showing destructive thermal increases near the tumors’ blood supplies.

"Based on these encouraging early results, we conclude that the use of magnetic resonance temperature imaging and gold nanoshells hold the very real possibility of meeting the long-sought goal of improving the precision of thermal ablation, while sparing healthy tissue," explains M.D.
Anderson Cancer Center's R.J. Stafford, Ph.D. "Temperature imaging and guidance is an invaluable tool furthering this approach as it moves from feasibility studies to future use in human clinical trials."

For more information:

Source: American Association of Physicists in Medicine

Related Content

Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...
FDA Approves Exablate Neuro for Tremor-Dominant Parkinson's Treatment
Technology | Focused Ultrasound Therapy | December 21, 2018
Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
News | Radiation Dose Management | September 24, 2018
AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat